Experimental Triple-Drug cocktail targets Hard-to-Treat breast cancer

NCT ID NCT07161791

Not yet recruiting Disease control Sponsor: Harbin Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study will test a combination of three drugs—camrelizumab (an immunotherapy), pirfenidone (an anti-fibrotic drug), and standard chemotherapy—in 12 women with advanced triple-negative breast cancer that has already been treated with immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. The trial is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab (immune therapy), pirfenidone (anti-fibrotic drug), and chemotherapy (paclitaxel or capecitabine)
What this could lead to: If it works, this combination could offer a new treatment option for advanced triple-negative breast cancer that has stopped responding to initial therapy.
What could go wrong: This is a very small, early-phase trial with only 12 people, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.